Erstnachweis der Zierlichen Moosjungfer (Leucorrhinia caudalis) in Sachsen-Anhalt

Bis 2003 konnte die Art der Zierlichen Moosjungfer Leucorrhinia caudalis (Charpentier, 1840) nicht nachgewiesen werden. Im Jahre 2008 gelang nunmehr auch für Sachsen-Anhalt in Sekundärbiotopen (Abgrabungsgewässern) erstmals der Nachweis der Zierlichen Moosjungfer. L. caudalis ist damit die 70. in Sachsen-Anhalt nachgewiesene Libellenart. Sie gilt in Deutschland als „vom Aussterben bedroht“ und ist nach Anhang IV der FFH-Richtlinie als Art von gemeinschaftlichem Interesse zu betrachten

Circumpolar mapping of permafrost temperature and thaw depth in the ESA Permafrost CCI project

Permafrost is an Essential Climate Variable (ECV) within the Global Climate Observing System (GCOS), which is characterized by subsurface temperatures and the depth of the seasonal thaw layer. Complementing ground-based monitoring networks, the Permafrost CCI project funded by the European Space Agency (ESA) 2018-2021 will establish Earth Observation (EO) based products for the permafrost ECV spanning the last two decades. Since ground temperature and thaw depth cannot be directly observed from space-borne sensors, we will ingest a variety of satellite and reanalysis data in a ground thermal model, which allows to quantitatively characterize the changing permafrost systems in Arctic and High-Mountain areas. As recently demonstrated for the Lena River Delta in Northern Siberia, the algorithm uses remotely sensed data sets of Land Surface Temperature (LST), Snow Water Equivalent (SWE) and landcover to drive the transient permafrost model CryoGrid 2, which yields ground temperature at various depths, in addition to thaw depth. For the circumpolar CCI product, we aim for a spatial resolution of 1km, and ensemble runs will be performed for each pixel to represent the subgrid variability of snow and land cover. The performance of the transient algorithm crucially depends on the correct representation of ground properties, in particular ice and organic contents. Therefore, the project will compile a new subsurface stratigraphy product which also holds great potential for improving Earth System Model results in permafrost environments. We present simulation runs for various permafrost regions and characterize the accuracy and ability to reproduce trends against ground-based data. Finally, we evaluate the feasibility of future “permafrost reanalysis” products, exploiting the information content of various satellite products to deliver the best possible estimate for the permafrost thermal state over a range of spatial scales

Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM

The international precision oncology program INFORM enrolls relapsed/refractory pediatric cancer patients for comprehensive molecular analysis. We report a two-year pilot study implementing ex vivo drug sensitivity profiling (DSP) using a library of 75–78 clinically relevant drugs. We included 132 viable tumor samples from 35 pediatric oncology centers in seven countries. DSP was conducted on multicellular fresh tumor tissue spheroid cultures in 384-well plates with an overall mean processing time of three weeks. In 89 cases (67%), sufficient viable tissue was received; 69 (78%) passed internal quality controls. The DSP results matched the identified molecular targets, including BRAF, ALK, MET, and TP53 status. Drug vulnerabilities were identified in 80% of cases lacking actionable (very) high-evidence molecular events, adding value to the molecular data. Striking parallels between clinical courses and the DSP results were observed in selected patients. Overall, DSP in clinical real-time is feasible in international multicenter precision oncology programs

Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM

The international precision oncology program INFORM enrolls relapsed/refractory pediatric cancer patients for comprehensive molecular analysis. We report a two-year pilot study implementing ex vivo drug sensitivity profiling (DSP) using a library of 75-78 clinically relevant drugs. We included 132 viable tumor samples from 35 pediatric oncology centers in seven countries. DSP was conducted on multicellular fresh tumor tissue spheroid cultures in 384-well plates with an overall mean processing time of three weeks. In 89 cases (67%), sufficient viable tissue was received; 69 (78%) passed internal quality controls. The DSP results matched the identified molecular targets, including BRAF, ALK, MET, and TP53 status. Drug vulnerabilities were identified in 80% of cases lacking actionable (very) high-evidence molecular events, adding value to the molecular data. Striking parallels between clinical courses and the DSP results were observed in selected patients. Overall, DSP in clinical real-time is feasible in international multicenter precision oncology programs.Peer reviewe

Vorbereitung des Uebergangs koerperbehinderter Jugendlicher von der Schule ins Arbeitsleben Forschungsprojekt 1.5.1990 bis 30.11.1994

IAB-96-520-53 BC 701 / FIZ - Fachinformationszzentrum Karlsruhe / TIB - Technische InformationsbibliothekSIGLEDEGerman

Analyses of the genomic methylation status of the human cyclin A1 promoter by a novel real-time PCR-based methodology

AbstractThe role of CpG methylation in the regulation of tissue-specific gene expression is highly controversial. Cyclin A1 is a tissue-specifically expressed gene that is strongly methylated in non-expressing tumor cell lines. We have established a novel real-time PCR method to quantitate genomic CpG methylation of the cyclin A1 promoter. Genomic DNA samples from different human organs were treated with bisulfite and amplified with methylation-specific primers and with primers amplifying methylated as well as non-methylated DNA. PCR product quantitation was obtained by using a fluorogenic probe labeled with FAM and TAMRA. These analyses demonstrated that the human cyclin A1 promoter was methylated in kidney, colon, spleen, testis, and small intestine, but not in brain, liver, pancreas, or heart. Expression of cyclin A1 was predominantly found in testis. Low level expression of cyclin A1 was present in spleen, prostate, leukocytes, colon, and thymus. Taken together, our data provide evidence that CpG methylation patterns of the human cyclin A1 promoter in human organs do not generally correlate with cyclin A1 gene expression in vivo